Today, biotechnology company NovaBay Pharmaceuticals announced it has received approval from the World Health Organization for the international nonproprietary name (INN) "auriclosene" for NVC-422, its lead Aganocide compound. Facilitating the identification of active pharmaceutical ingredients, INNs have unique, globally recognized names.
Aganocides, NovaBay's first-in-class topical antimicrobial compounds, are active against viruses, fungi, and bacteria - including the bacteria that grow and thrive under biofilm. In-vitro and in-vivo tests have shown that these non-systemic, non-antibiotic compounds don't give rise to bacterial or fungal resistance.
Currently, Phase 2 studies are ongoing for auriclosene in urology, ophthalmology, and dermatology. Data from three Phase 2 trials is expected sometime this year, and Phase 3 registration trials are expected to commence in 2014.
Obtaining the INN for this lead clinical compound signifies that NovaBay is on track with its clinical development, and the company expects to progress into Phase 3 development in each of its three Aganocide programs. NovaBay additionally plans to conduct a Phase 2a proof-of-concept study for auriclosene in another ophthalmic indication. NVC-422 - now auriclosene - is the first of the company's proprietary Aganocides to receive a nonproprietary name.
For more information, visit novabay.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net